Menovag (Estradiol Hemihydrate)

Menovag, an estrogenic agent, is used in hormone replacement therapy to address conditions related to estrogen deficiency.

• Menopausal symptoms: reduction of hot flashes, night sweats, and mood disturbances.
• Atrophic vaginitis: restoration of vaginal epithelium, decreasing dryness and discomfort.
• Postmenopausal urogenital atrophy: improvement of urinary symptoms and sexual function.

• Estradiol hemihydrate binds to estrogen receptors ERα and ERβ in target tissues, initiating receptor dimerization and recruitment of co‑activators. This modulates gene transcription, leading to increased synthesis of proteins that maintain vaginal mucosal integrity, regulate thermoregulation, and support bone density, thereby producing the therapeutic estrogenic effects.

Vaginal administration of estradiol can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Vaginal irritation or burning: mild discomfort at the application site.
• Increased vaginal discharge: watery or mucous secretion.
• Breast tenderness: mild swelling or soreness.
• Headache: transient pain.
• Nausea: occasional upset stomach.
• Itching: localized pruritus.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Endometrial hyperplasia: abnormal thickening of the uterine lining.
• Liver dysfunction: jaundice or elevated enzymes.
• Vision changes: sudden loss of vision or blurred sight.

When prescribing Menovag, clinicians should consider several precautionary measures to ensure safe use.

• Assess contraindications: history of thromboembolic disease or estrogen‑dependent tumors.
• Monitor breast symptoms: report any new lumps or discharge.
• Avoid use with estrogen‑dependent neoplasms: such as certain breast cancers.
• Use the lowest effective dose: to achieve symptom control while minimizing risk.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Estradiol hemihydrate may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Combined oral contraceptives containing estrogen: increased risk of thrombosis.
• Hormone therapy with progestins: potential additive estrogenic effects.
• Anticoagulants (e.g., warfarin): heightened clotting risk.

Moderate Interactions (Monitor Closely)

• Tamoxifen: possible reduction in anti‑estrogenic activity.
• Selective serotonin reuptake inhibitors (SSRIs): may increase nausea.
• Lithium: potential alteration of hormone levels and renal handling.